Neurological associations of COVID-19 by Ellul, Mark A et al.
 1 
Neurological Associations of COVID-19 
 
 
 
Authors  
 
Mark Ellul1,2, Laura Benjamin3, Bhagteshwar Singh1,4,5, Suzannah Lant1, Benedict Daniel Michael1,2, 
Ava Easton6, Rachel Kneen7, Sylviane Defres1,4, Jim Sejvar8, Tom Solomon1,2,4 
 
Affiliations 
 
1. National Institute for Health Research Health Protection Research Unit on Emerging and Zoonotic 
Infections, Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, 
Liverpool, UK  
2. The Walton Centre NHS Foundation Trust, Liverpool, UK  
3. University College London Queen Square Institute of Neurology, London, UK 
4. Tropical and Infectious Diseases Unit, Royal Liverpool and Broadgreen University Hospitals NHS 
Trust, Liverpool, UK 
5. Christian Medical College, Vellore, India 
6. Encephalitis Society, Malton, UK 
7. Alder Hey Children’s NHS Foundation Trust, Liverpool, UK 
8. Division of High-Consequence Pathogens and Pathology, National Center for Emerging and 
Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA 
 
Author Statement 
 
MAE, BDM, JS and TS devised the idea for the study.  MAE, LB, BS, SL, BDM, RK, SD, JS and TS 
contributed to the literature search.  MAE, LB, BS, SL, BDM and TS designed and drafted the figures.  
MAE, LB, BS, SL, BDM, RK, SD, JS and TS prepared the initial manuscript draft. All authors contributed 
to, reviewed and approved the final draft of the paper. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Summary  
 
Background  
 
The COVID-19 pandemic, caused by SARS-CoV-2, is of a scale not seen since the 1918 influenza 
pandemic. Although the predominant clinical presentation is with respiratory disease, neurological 
manifestations are being recognised increasingly. Based on knowledge of other coronaviruses, 
especially those that caused the SARS and MERS epidemics, we might expect to see rare cases of 
central nervous system (CNS) and peripheral nervous system (PNS) disease caused by SARS-CoV-2. 
 
Recent developments  
 
A growing number of case reports and series describe a wide array of neurological manifestations, 
but many lack detail, reflecting the challenge of studying such patients. Encephalopathy is relatively 
common, being reported for 16 (7.5%) of 214 hospitalised COVID-19 patients in Wuhan, China, and 
40 (69%) of 58 in intensive care with COVID-19 in France. Encephalitis has been described in 8 
patients to date, and Guillain-Barré syndrome in 19 patients. SARS-CoV-2 is detected in the 
cerebrospinal fluid of some patients. Anosmia and ageusia are common and may occur in the 
absence of other clinical features. Unexpectedly, acute cerebrovascular disease is also emerging as 
an important complication, reported for 88 patients, mostly with ischaemic stroke, and possibly due 
to a pro-inflammatory hypercoagulable state with elevated CRP, D-dimer, and ferritin. 
 
Where next?  
 
Careful clinical, diagnostic and epidemiological studies are needed to help define the manifestations 
and burden of neurological disease caused by SARS-CoV-2. Precise case definitions must be used to 
distinguish non-specific complications of severe disease, such as hypoxic encephalopathy and critical 
care neuropathy, from those caused directly or indirectly by the virus; these include infectious, para- 
and post-infectious encephalitis, hypercoagulable states leading to stroke, and acute neuropathies 
such as Guillain-Barré syndrome. Recognising SARS-CoV-2 neurological disease in patients whose 
respiratory infection is mild or asymptomatic may prove challenging, especially if the primary COVID-
19 illness occurred weeks earlier. The proportion of infections leading to neurological disease will 
remain small. However, these patients may be left with severe neurological sequelae. With so much 
of the population infected, the overall number of neurological patients, and their associated health, 
social and economic costs, may be large. Healthcare planners and policymakers must prepare for 
this eventuality. 
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Introduction  
 
As of 19th May 2020, the COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has 
resulted in more than 4.8 million confirmed cases worldwide, and more than 300,000 deaths. It is 
the largest and most serious pandemic since the 1918 influenza pandemic. Whilst the most common 
and important presentation is with respiratory disease, there are increasing reports of neurological 
features. These appear to be a combination of non-specific complications of systemic disease, or 
infection and/or inflammation of the nervous system and vasculature, which may be para- or post-
infectious. In this rapid review, we consider which neurological manifestations might be expected for 
COVID-19, given what we know about related coronaviruses and respiratory viruses more broadly; 
we summarize the evidence to date for COVID-19, and examine putative disease mechanisms; 
finally, we suggest a framework for investigating patients with suspected COVID-19 neurological 
disease to support clinico-epidemiological, disease mechanism and treatment studies. 
 
 
Evidence from other viruses  
 
Before SARS-CoV-2, six coronaviruses were known to infect humans. Four that cause seasonal, 
predominantly mild respiratory illness have a high incidence globally, accounting for about 15-30% 
of upper respiratory tract infections.1 Two have led to major epidemics with deaths principally from 
respiratory disease; Severe Acute Respiratory Syndrome (SARS) was caused by SARS-CoV in 2002-3 
and Middle East Respiratory Syndrome (MERS) by MERS-CoV in 2012.2,3 Both the more innocuous 
coronaviruses and these epidemic strains have been associated with occasional disease of the 
central nervous system (CNS) and peripheral nervous system (PNS). 
 
Both CNS and PNS disease were reported following SARS (appendix, page 10-11).  SARS-CoV was 
detected in CSF by RT-PCR in two of three cases of encephalopathy with seizures; 4,5 it was cultured 
from brain tissue at autopsy in the third.6 Four patients with severe SARS developed neuromuscular 
disease, predominantly motor neuropathy, myopathy, or both,7 which may have been SARS-specific 
or secondary to critical illness.8 CNS involvement was described for five adults with MERS; two had 
acute disseminated encephalomyelitis (ADEM), two had cerebrovascular disease, and one had 
Bickerstaff’s brainstem encephalitis.9–11 Neuropathy was described for 3 patients.9,11 HCoV-OC43, a 
seasonal coronavirus, has caused encephalitis in an infant with severe combined 
immunodeficiency,12 and ADEM in an older immunocompetent child.13 Headache, neck stiffness, and 
seizures were described among 22 children (median age 36 months) with suspected CNS infection 
and coronavirus IgM antibodies in serum and/or CSF.14 Ten had a CSF pleiocytosis, and eight had 
brain imaging abnormalities. All 22 made a full recovery.14 
 
Neurological complications have been described for other respiratory viruses, particularly seasonal 
and pandemic influenza.1 These include acute necrotising encephalopathy associated with mutations 
in the RANBP2 gene, acute infantile encephalopathy, and acute haemorrhagic leukoencephalopathy 
and myelopathy in adults.15,16 The estimated incidence of neurological disorders during the 2009 
H1N1 influenza pandemic was 1.2 per 100,000, with children affected more than adults.17–20 The 
1918 H1N1 “Spanish” influenza pandemic was associated with post-infectious encephalitis 
lethargica.21  
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Projected epidemiology of COVID-19 -associated neurological disease  
Although neurological complications are rare in SARS, MERS and COVID-19, the scale of the current 
pandemic means that even a very small proportion could build up to a large number of cases. Table 
1 shows that for SARS and MERS, the minimum prevalence of CNS complications ranged from 0.04% 
to 0.2% and for PNS complications from 0.05% to 0.16%; the extrapolated number of cases with 
neurological complications of COVID-19, based on these related viruses, is also shown. Given the 4.8 
million cases of COVID-19 globally as of 19th May 2020, this projects to a total of 1805-9671 patients 
with CNS, and 2407-7737 with PNS complications. These numbers, which don’t include the 
increasingly important syndromes of stroke-associated COVID-19 infection, will rise as the pandemic 
continues.  
 
RECENT DEVELOPMENTS 
COVID-19 and neurological disease  
As the COVID-19 pandemic progresses there are increasing reports of neurological manifestations 
(Table 2). These can be considered as direct effects of the virus on the nervous system, para- or 
post-infectious immune mediated disease, and neurological complications of the systemic effects of 
COVID-19.  The challenges in managing patients with a highly contagious infection, and the 
overwhelming numbers of cases mean that many early reports lack detail, have limited CSF analysis, 
imaging or follow up, and appear on non-peer-reviewed websites. 
 
 
Encephalitis 
 
Encephalitis is inflammation of the brain parenchyma, usually caused by an infection, or the body’s 
immune defences. Although strictly speaking a pathological diagnosis, for practical purposes clinical 
evidence of brain inflammation is accepted, such as a CSF pleiocytosis, imaging changes or focal 
abnormalities on electroencephalogram (EEG). Detection of virus in the CSF per se does not diagnose 
encephalitis if there is no evidence of brain inflammation (Table 3; appendix, page 3).22   
 
As of 19th May 2020, eight adults (four women) aged 24-78 (median 62) years have been described 
who had encephalitis associated with COVID-19, mostly diagnosed through a nasal/nasopharyngeal 
swab.23–29 Neurological features mostly started from the time of respiratory symptom onset to 17 
days after, though in one 60-year-old man confusion preceded cough and fever by two days (Figure 
2a);25 two patients had fever only, with no respiratory features.26,29 The neurological manifestations 
were typical for encephalitis, with irritability, confusion and reduced consciousness, sometimes 
associated with seizures; three patients also had neck stiffness24–26 and another had psychotic 
symptoms.30 A 40-year-old man developed ataxia, oscillopsia, hiccups and bilateral facial weakness.27 
CSF, reported for six patients showed a pleiocytosis in five, mostly lymphocytic, and was normal in 
one. Four had CSF PCR performed for SARS-CoV-2, of whom one was positive – a 24-year-old man 
with encephalitis, minor respiratory symptoms and “ground glass” changes on chest CT, who had a 
PCR negative respiratory sample.24 Few publications reported a comprehensive work up for other 
causes of encephalitis.30 Brain imaging was normal or had no acute changes for six patients, and 
showed high signal intensity in two, including temporal lobe changes in one;23 the patient with 
ataxia had a cerebellar lesion that extended into the spinal cord.27 Electroencephalography was 
performed in five patients. Two had generalised slowing, two had focal abnormalities; one, who 
presented with psychotic symptoms followed by a seizure, was found to be in non-convulsive status 
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epilepticus.30 One patient responded quickly to high dose steroids,25 but for most there was no 
specific treatment beyond anticonvulsants, antiviral and antibiotic medication.  
 
There is no specific treatment for SARS-CoV-2 encephalitis. As for other forms of encephalitis, there 
will be questions around the relative contributions of viral damage and host inflammatory response, 
and whether corticosteroids might be useful. Clinical trials seem unlikely, given current numbers. 
   
Other encephalopathies 
 
Encephalopathy is the syndrome of altered mental status, which can manifest as changed 
personality, behaviour or consciousness. In encephalopathic SARS-CoV-2 patients, in whom brain 
inflammation has not been proven, the wide range of other causes to consider includes hypoxia, 
drugs, toxins, and metabolic derangements (appendix, page 3).22  
 
The largest study to date, from Wuhan where the pandemic began, described retrospectively 214 
patients with COVID-19, of whom 53 had CNS symptoms including dizziness (36 patients, 46.1%), 
headache (28,35.9%), and impaired consciousness (16, 20.5%), 27 had severe respiratory disease but 
there was little further detail.31  In a French series of 58 intensive care patients with COVID-19, 49 
had neurological complications, including 40 (69%) with encephalopathy, and 39 (67%) with 
corticospinal tract signs.32 MRI in 13 patients showed leptomeningeal enhancement for eight and 
acute ischemic change for two (see below); CSF examination for 7 patients showed no pleiocytosis. 
Fifteen (33%) of 45 who had been discharged had a dysexecutive syndrome. In addition to these 
series, there has been a handful of case reports, including an encephalopathic woman with imaging 
changes consistent with acute necrotising encephalopathy23 (Figure 1a) and a fatal case in which 
viral particles were found in endothelial cells and neural tissue, though there was no indication of 
whether this was associated with inflammation.33 
 
There have been several reports of seizures in children with SARS-CoV-2 infection. Paroxysmal 
episodes consistent with seizures were described in two infants with no respiratory symptoms but 
SARS-CoV-2 on nasopharyngeal swab.34,35 Both made a good recovery. In one series of 168 children 
hospitalised with COVID-19, seizures were described for five (3%) children, of whom three had pre-
existing epilepsy and one had previous febrile seizures.36 
 
Acute disseminated encephalomyelitis (ADEM) and myelitis  
 
ADEM is a syndrome of multifocal demyelination, typically occurring weeks after an infection, which 
generally presents with focal neurological symptoms often with encephalopathy.37 Two case reports 
describe middle-aged women with ADEM and SARS-CoV-2 detected on respiratory swabs. One 
developed dysphagia, dysarthria and encephalopathy 9 days after onset of headache and myalgia.38  
The other presented with seizures and reduced consciousness and required intubation for 
respiratory failure.39  Both had normal CSF and high signal intensities on MRI typical of ADEM. They 
both improved after treatment, the first with IVIG, the second with steroids. To date there is just a 
single report of myelitis (inflammation of the spinal cord) associated with COVID-19. A 66-year-old 
man in Wuhan, China developed fever, fatigue and then acute flaccid paraparesis with incontinence. 
Examination demonstrated hyporeflexia and a sensory level at T10. He was treated with 
dexamethasone and IVIG and was discharged for rehabilitation.40   
 
ADEM and myelitis, usually considered post-infectious diseases, are treated typically with 
corticosteroids or other immunotherapies. In these para-infectious cases, with SARS-CoV-2 
detectable at presentation, clinicians may need to be more cautious, especially if virus is detected in 
the CSF. 
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Cerebrovascular disease  
 
As COVID-19 has spread around the world, evidence has grown for an association with 
cerebrovascular disease, as well as other forms of vascular disease. There were cerebrovascular 
manifestations for 13 (5.9%) of 221 COVID-19 patients in an early retrospective case series from 
Wuhan: 11 (5%) developed ischaemic stroke, one (0·5%) had intracerebral haemorrhage, and one 
(0·5%) cerebral venous sinus thrombosis.41 In Brescia, Italy 43 (77%) of 56 SARS-CoV-2 positive 
patients admitted to one neurology unit had cerebrovascular disease: 35 ischaemic and three 
haemorrhagic stroke, and five with transient ischaemic attacks.42 In total 88 patients with ischaemic 
and 8 with haemorrhagic stroke41–45 have been reported, 18 (19%) of who died (Table 2; appendix, 
pages 12-22)  
 
Most patients were over 60 years old, many with known risk factors for cerebrovascular disease, 
especially hypertension, diabetes mellitus, hyperlipidaemia, and vascular disease.41,45–48 Younger 
stroke patients have also been reported.43,47,49–51 In one New York hospital, five young stroke 
patients with SARS-CoV2 were admitted in just two weeks, whereas the average number of young 
stroke admissions per two weeks in the preceding year was 0·73.51 Two had no other symptoms of 
COVID-19. All had large vessel ischaemic strokes. Cerebrovascular symptoms began a median (range) 
of 9·5 (0-33) days after the onset of respiratory illness, though in one patient the stroke preceded 
reparatory features,31 and in five there were only cerebrovascular symptoms.43,48,49,51 
 
In a couple of patients, ischaemic stroke has been associated with thrombus in the aorta,49,52 and 
indeed multiple infarcts have been reported for these and other patients,46,47,53 sometimes 
associated with arterial thrombosis and limb ischaemia.46,53  Concurrent deep vein thrombosis and 
pulmonary embolism has been found for other stroke patients.47,49 Arterial and venous imaging is 
clearly essential for COVID-19 patients with acute cerebrovascular events. Small asymptomatic 
infarcts identified on MRI only have also been described.32 Blood D-dimer concentration was raised 
in many COVID-19 stroke patients, consistent with a pro-inflammatory, coagulopathic state in the 
setting of critical illness.41,45–52  Positive lupus anticoagulant, anticardiolipin and anti–β2-
glycoprotein-1 antibodies have also been reported in COVID-19 associated stroke,46 47 though these 
can be raised in other critical illness, including infections. 
 
Immediate anticoagulation with low molecular weight heparin has been recommended for COVID-19 
patients, to reduce the risk of thrombotic disease.54 This might also reduce COVID-19-associated 
ischaemic stroke, but it must be balanced against the risk of intracranial haemorrhage, including 
haemorrhagic transformation of an acute infarct. Several randomised controlled trials are looking at 
the role of anticoagulation in COVID-19 patients, including the impact on stroke incidence.  
 
 
Peripheral nervous system and muscle disease  
 
Guillain-Barré syndrome (GBS) is an acute polyradiculopathy characterized by rapidly progressive 
symmetrical limb weakness, with sensory symptoms, and areflexia, with or without facial weakness, 
though there are several variants. To date, 19 patients (six female) with GBS or its variants and SARS-
CoV-2 infection have been reported, with a median (range) age of 62·5 (23-77) years. For the 
number of SARS-CoV-2 infections world-wide, incidence is not particularly above what might be 
expected.55 Neurological symptoms started typically 7 (range -7-24) days after respiratory or 
systemic features (Figure 2a), although two patients developed febrile illness 7 days after the onset 
of GBS;56,57 on hospital admission one had a positive swab for SARS-CoV-2, and the other had 
lymphocytopenia and thrombocytopenia, characteristic for SARS-CoV-2 infection. Three patients had 
diarrhoea before the onset of neurological disease. 
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Eleven patients had classical GBS with weakness of all four limbs with or without sensory loss,56,58–65 
three had a paraparetic variant with leg weakness only,57,65,66 and one had lower limb paraesthesia.65 
Four of these patients had facial nerve involvement, five had dysphagia, and eight developed 
respiratory failure. Three had autonomic complications, one with hypertension and two with 
sphincter dysfunction. Electrophysiological studies, performed in 12 patients, were consistent with 
demyelinating disease in eight, and axonal disease in four.  
 
Two patients had the Miller Fisher variant of GBS with ophthalmoplegia, ataxia and areflexia;67,68 one 
also had anosmia and ageusia (see below), and was positive for anti-GD1b-IgG. One patient had 
bilateral, and one patient unilateral, abducens palsy,67,68 and another had an acute vestibular 
syndrome with horizontal nystagmus and oscillopsia.69 
 
For 16 patients, SARS-CoV-2 was detected in a respiratory swab, for two the sample was not 
specified; one patient was also positive for rhinovirus. One patient was diagnosed by a blood 
antibody test. A lumbar puncture was performed for 13 patients, and showed albuminocytological 
dissociation in 11. SARS-CoV-2 was not detected in any CSF samples. Testing for other pathogens 
commonly associated with GBS  was reported for just four patients.60,63,65,66  Fifteen patients were 
treated with intravenous immunoglobulin; eight, all with classical GBS, were admitted to intensive 
care for ventilatory support, two of these died.59,61 Twelve improved and five had ongoing disability 
at discharge.  
 
Muscle injury association with raised creatine kinase affected 23 (11%) of the 214 patients in the 
Wuhan series.25 Rhabdomyolysis due to COVID-19 has also been reported.70,71 
 
Loss of smell (anosmia) and taste (ageusia) have emerged as common symptoms of COVID-19, either 
with other features or in isolation, suggesting they may be useful diagnostic markers.72 A study of 
259 patients, including 68 positive for SARS-CoV-2, found abnormal smell and taste were both 
strongly associated with COVID-19.73 In a European study, olfactory dysfunction was reported for 
357 (86%) of 417 COVID-19 patients; 342 (89%) reported gustatory disorders.74 These symptoms 
were reported more frequently for COVID-19 patients than for a historical cohort of influenza 
patients.75 Subclinical deficits in smell and/or taste have also been detected.76,77  Although these 
symptoms can occur in any respiratory infection due to coryza, the fact they occur in isolation of 
other symptoms suggest there is involvement of the olfactory nerve. 
 
Disease mechanisms  
Infection and inflammation of the central and peripheral nervous system  
 
As for other neurotropic viruses, there are critical questions for SARS-CoV-2 around routes of entry 
into the nervous system, and the relative contribution of virus infection versus host response in the 
subsequent damage (Figure 2b). 
 
Viral entry to the brain via the olfactory bulb, the only part of the CNS not protected by dura, is one 
plausible route for SARS-CoV-2, especially given the anosmia in COVID-19. This is thought to be a 
route of entry for herpes simplex virus, the most common cause of sporadic viral encephalitis.78 In 
mouse models, following intranasal injection HCoV-OC43 invades the CNS by the olfactory route.79 
Alternative entry routes include carriage across the blood brain barrier, following viraemia, or via 
infected leukocytes.1 The angiotensin converting enzyme 2 (ACE-2) receptor, which SARS-CoV-2 
binds to for entry into cells,80 is found in brain vascular endothelium and smooth muscle.81 SARS-
CoV-2 replicates in neuronal cells in vitro.82  
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Damage within the CNS or PNS may be caused directly by virus or by the body’s innate and adaptive 
immune responses to infection. Data so far do not suggest that SARS-CoV-2 or related coronaviruses 
are highly neurovirulent, unlike herpes simplex virus, some enteroviruses and some arthropod-
borne viruses, which can cause rampant destruction of neurons.78  
 
Autopsy material from a patient who developed encephalopathy weeks after presenting with SARS 
showed oedema, neuronal necrosis and broad gliocyte hyperplasia.6 Immunohistochemical staining 
demonstrated SARS-CoV in the brain was associated with elevated expression of monokine induced 
by interferon-g (Mig) and infiltration of monocytes/macrophages plus T lymphocytes. These findings 
are consistent with viral CNS entry triggering infiltration of immune cells and cytokine/chemokine 
release, which contributed to tissue damage.  
 
There has been little work on disease mechanisms for coronavirus PNS disease. By comparison with 
other viruses, it would not be surprising to see immune-mediated disease, e.g. GBS; direct anterior 
horn cell viral damage causing acute flaccid myelitis might also be expected.83 
 
Cerebrovascular disease 
 
Early indicators suggest cerebrovascular disease in COVID-19 may be due to a coagulopathy.  SARS-
CoV-2 can cause damage to endothelial cells activating inflammatory and thrombotic pathways.84 
Endothelial cell infection and/or monocyte activation, upregulation of tissue factors, and the release 
of microparticles activating the thrombotic pathway and causing microangiopathy may occur for 
SARS-CoV-2, as for other viruses.85,86 The latter is postulated to represent part of the secondary 
haemophagocytic lymphohistiocytosis spectrum described in severe COVID-19.87 Thrombocytopenia 
with elevated D-dimer and CRP in severe COVID-19 and stroke are consistent with a virus-associated 
microangiopathic process.41 Endothelial dysfunction can potentially lead to micro- and macro-
vascular, arterial and potentially venous complications in the brain, as described systemically.88 
 
Acute ischaemic stroke may also occur through the early inflammatory process following acute 
infection destabilising a carotid plaque or triggering atrial fibrillation.89 A vasculitis process similar to 
that for varicella zoster virus, where viral replication in the cerebral arterial wall triggers local 
inflammation,90 is also plausible:  endothelial infection by SARS-CoV-2 with inflammation and 
apoptosis of endothelial cells has been shown in kidney, heart, bowel and lung at autopsy,84 but 
cerebral vessels have not yet been investigated. 
 
WHERE NEXT? 
Investigating for neurological disease 
As SARS-CoV-2 continues to spread, and patients with neurological symptoms are seen increasingly, 
it is essential that the desire to publish quickly is balanced with the need for careful clinical, 
diagnostic and epidemiological studies. Clinicians must adopt a methodical approach to investigating 
patients with possible COVID-19 neurological disease, and systematically consider the evidence for 
viral infection, and the presenting clinical diagnosis, using definitions that distinguish confirmed, 
probable, and possible cases (Table 3; appendix, page 2-8). 
 
Given that SARS-CoV-2 causes a large number of asymptomatic or mildly symptomatic infections, it 
is crucial to remember that patients with neurological disease from other causes may be infected 
coincidentally with the virus, even in hospital through nosocomial transmission. A full work-up, 
lacking for many reports to date, is needed to rule out other established causes of brain infections 
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before attributing disease to COVID-19.22,91 Distinguishing between nasopharyngeal SARS-CoV-2 
infection and nervous system infection is also critical (Table 3). 
 
For patients with altered consciousness or agitation, consider all causes of encephalopathy, 
including hypoxia, drugs, toxins, and metabolic derangement; only diagnose encephalitis if there is 
clinical evidence of brain inflammation such as a CSF pleiocytosis, imaging changes, focal seizures, or 
histological changes (appendix, page 3).22 Even if virus is detected in the CSF, encephalitis should not 
be diagnosed unless there is evidence of brain inflammation. For patients with possible peripheral 
nerve disease, aim to perform CSF examination including albuminocytologic ratio, nerve conduction 
studies and electromyography during recovery, even if they cannot be done acutely. 
 
In patients with neuropathy, cerebrovascular disease or ADEM, where the damage is likely caused by 
host response to viral infection, establishing causality is even more challenging, especially if patients 
present after virus has cleared from the nasopharynx. Clinical case definitions for COVID-19, based 
on the history and typical findings for chest imaging and blood investigations (Table 3) will be useful. 
For stroke patients, consider cerebral angiography, intracranial vessel wall imaging and, if necessary, 
brain biopsy, looking for vasculitis. The apparent high incidence of cerebrovascular disease in 
patients with COVID-19, with predominantly large vessel disease and markers of a highly 
prothrombotic state, suggest a causal relationship. However, the high prevalence of the virus during 
the pandemic, and the fact that most stroke patients have other risk factors, mean it is hard to be 
sure about causation. The link with SARS-CoV-2 may ultimately need to be proven by careful case-
control studies. 
 
In investigating patients with limb weakness and sensory change it is critical to distinguish between 
disease of the peripheral nerves such as GBS, and inflammation of the spinal cord, which can present 
with flaccid paralysis if the anterior horn cells are involved.83 CSF examination, neurophysiological 
studies and spinal imaging are essential. 
 
For patients on intensive care, determining whether neuropathy, myopathy, encephalopathy or 
cerebrovascular disease are non-specific manifestations of critical illness or are specific to the virus 
itself may be especially challenging; there are no reliable markers for critical illness, though it tends 
to occur after several weeks.8 Up to 70% of patients with sepsis may develop encephalopathy or 
polyneuropathy.92 In the Wuhan series, neurological complications were more common in those 
with severe disease, suggesting some of the neurological manifestations were related to critical 
illness.93,94 
 
Conclusion and future directions  
Given knowledge of other coronaviruses and respiratory viruses, the wide range of CNS and PNS 
associations with COVID-19 is not surprising. Currently the focus is on neurological complications of 
patients with obvious COVID-19 respiratory disease; however, we are likely to see neurological 
disease in patients with few or no typical features of COVID-19, based on knowledge of other 
epidemic viral infections and cases reported so far.95 Hypercoagulable states and cerebrovascular 
disease, which have been seen rarely for some acute viral infections, are emerging as an important 
neurological complication of COVID-19. 
 
Overall, the proportion of patients with neurological manifestations is small compared with 
respiratory disease. However, the continuing pandemic, and expectation that 50-80% of the world’s 
population may be infected before herd immunity develops, suggest that the overall number of 
patients with neurological disease may become large. Neurological complications, particularly 
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encephalitis and stroke can cause lifelong disability with associated long-term care needs, and 
associated health, social and economic costs, may be considerable.Healthcare planners and 
policymakers need to be aware of the growing burden. 
 
Careful clinical, diagnostic and epidemiological studies are needed to help define the neurological 
disease manifestations and burden. This will involve collaboration of a range of clinical and research 
expertise, and harmonised approaches across regions, using standardised case record forms such as 
on https://braininfectionsglobal.tghn.org/covid-neuro-network/ .  
 
 
Search Strategy and selection criteria   
 
We searched PubMed and Scopus for articles on COVID-19 and neurological disease published in 
English from database inception to May 19, 2020 without language restrictions, using the terms 
“COVID-19”, “Novel coronavirus”, “SARS-CoV-2”, or “coronavirus” in combination with 
“neurological”, “nervous system”, “encephalitis”, “encephalopathy”, “seizure”, “ataxia”, 
"myelopathy", “Guillain-Barré syndrome”, “myopathy”, “peripheral neuropathy”, “neuritis”, 
“cerebrovascular”, “stroke”, “neuromuscular”, or “brain", modified as per requirements for each 
database’s search tool. We reviewed references of relevant studies for additional articles that might 
have been missed in the initial search. Experts in the field were consulted to ensure important 
preprints and unpublished studies were not missed. Articles were included on the basis of relevance 
and originality with regards to the topics covered in this Rapid Review. 
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Table 1. Estimated neurological disease case numbers associated with SARS, MERS and COVID-19        
 
 Total number of 
cases reported* 
SARS MERS COVID-19 Worldwide COVID-19  China COVID-19  USA COVID-19  UK  
 8096 2228 4872308 84500 1464232 246410  
    Extrapolated from Extrapolated from Extrapolated from Extrapolated from  
    SARS MERS SARS MERS SARS MERS SARS MERS  
 
   
minimum case 
count [lower 
and upper 95% 
CI bound] 
minimum case 
count [lower 
and upper 95% 
CI bound] 
minimum case 
count [lower 
and upper 95% 
CI bound] 
minimum case 
count [lower 
and upper 95% 
CI bound] 
minimum case 
count [lower 
and upper 95% 
CI bound] 
minimum case 
count [lower 
and upper 95% 
CI bound] 
minimum case 
count [lower 
and upper 95% 
CI bound] 
minimum case 
count [lower and 
upper 95% CI 
bound] 
 
 CNS disease, no. of 
patients [95% CI] 
(percentage of total 
coronavirus cases 
[95% CI])  
3 (0.04 
[0.01-0.10]) 
5 (0.20 
[0.06-0.5]) 1805 [370-5277] 9671 [3143-22539] 31 [6-92] 168 [55-391] 543 [111-1586] 2906 [944-6774] 91 [19-267] 489 [159-1140] 
 
 PNS disease, no. of 
patients [95% CI] 
(percentage of total 
coronavirus cases 
[95% CI])  
4 (0.05 
[0.01-0.13]) 
4 (0.16 
[0.04-0.41]) 2407 [658-6163] 7737 [2110-19786] 42 [11-107] 134 [37-343] 723 [198-1852] 2325 [634-5946] 122 [33-312] 391 [107-1001] 
 
 Total neurological 
disease, no. of 
patients [95% CI] 
(percentage of total 
coronavirus cases 
[95% CI])  
7 (0.09 
[0.03-0.18]) 
9 (0.36 
[0.16-0.68]) 4213 [1028-11440] 
17408 [5252-
42326] 73 [18-198] 302 [91-734] 1266 [309-3438] 5231 [1578-12720] 213 [52-579] 880 [266-2141] 
 
 
 
*calculated based on available data up until 19th May 2020; COVID-19 cases from https://coronavirus.jhu.edu/map.html 
95% confidence interval (CI) calculated with Clopper-Pearson exact method96 for proportions, to 6dp using https://epitools.ausvet.com.au/ciproportion 
 
 
 
  
  Table 1. Estimated neurological disease case numbers associated with COVID-19 extrapolated from SARS and MERS     
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Table 2. Selected reports of neurological disease associated with COVID-19  (abbreviated version – full table in the appendix) 
 
      First author and 
number of cases 
Clinical presentation SARS-CoV-2 
diagnostics 
Other pathogen and 
antibody investigations 
Relevant blood tests and 
radiology findings 
Neurological investigations (cerebrospinal fluid 
findings, neuroimaging, neurophysiology) 
 
Management, progress and outcome   
  Central Nervous System                         
     Encephalitis                         
      Moriguchi24 -1 
case 
24-year-old male presented 9 days 
after symptoms of fatigue, 
headache, fever - followed by a 
sore throat - with generalised 
seizures, reduced conscious level 
and meningism. 
RT-PCR negative in 
nasopharyngeal 
swab, positive in 
CSF. 
Serum: Anti-HSV 1 and VZV 
IgM antibodies tests were 
negative. 
Increased blood white cell count, 
neutrophil dominant, relatively 
decreased lymphocytes, increased 
CRP. CT Chest: small ground glass 
opacity in the right upper zone 
and bilaterally in lower zones.  
CSF: Clear, colourless. Raised opening pressure (320 
mmH20) and cell count (12/mm3 - 10 mononuclear 
and 2 polymorphonuclear cells) 
CT Head: no brain oedema. MRI brain: 
hyperintensity along the wall of the right lateral 
ventricle on diffusion weighted imaging, and 
hyperintense signal in the right medial temporal 
lobe and hippocampus on T2 weighted images 
 
Treated empirically for bacterial pneumonia and viral 
encephalitis. On admission, required intubation and 
mechanical ventilation due to seizures. Admitted to 
ICU. Still on intensive care at time of report (day 15) 
  
      Sohal28 - 1 case 72-year-old man presented with 
weakness and light headedness 
following a hypoglycaemic episode. 
Shortly after admission he had 
difficulty breathing and was noted 
to have altered mental status. On 
day two of admission he started to 
have seizures.  
RT-PCR positive- 
source not specified 
Blood: culture negative for 
bacterial growth. Influenza 
PCR: negative.  
ABG: pH of 7.13, PaO2 of 
68mmHg, PCO2 of 78mmHg. 
Raised BNP (541 pg/mL), troponin 
(0.35ng/mL), CRP (61 mg/L), LDH 
(230 U/L), as well as lymphopenia 
(0.5 k/cmm) and leukopenia at 
4000k/cmm. Chest X-ray: normal. 
CT chest: bibasilar opacities along 
with right lower lobe 
consolidation.  
 
CT head: no acute changes, chronic microvascular 
ischaemic changes.  
24h EEG showed six left temporal seizures and left 
temporal sharp waves which were epileptogenic 
Required intubation and ventilation, and was admitted 
to ICU. Became hypotensive requiring norepinephrine 
via central line. Hydroxychloroquine and azithromycin 
were started in addition to antimicrobials of 
vancomycin and piperacillin tazobactam. Onset of 
seizures - treated with levetiracetam and valproate 
but they were not controlled. Death on day 5 of 
illness.  
  
      Wong27 - 1 case 40-year-old male presented with 
ataxia, diplopia, oscillopsia and 
bilateral facial weakness – 
diagnosis: rhombencephalitis. 
13 days before he had fever and 
progressive shortness of breath on 
exertion, followed 10 days later by 
a productive cough and diarrhea.  
RT-PCR positive in 
nasopharyngeal 
swab. CSF RT-PCR 
not performed. 
Blood test: negative for 
hepatitis A, B, C, HIV 1 and 2, 
and syphilis antibody. CSF: 
negative bacterial culture. 
Sent for Anti MOG-IgG 
antibody and anti-aquaporin 
4 antibody testing but results 
not reported.  
Normal white cell count (7.0 × 10 
9/L) with lymphopaenia (1.2 × 
109/L), raised CRP (50 mg/L), 
abnormal LFTs (raised GGT 628 
U/L, ALT 542 U/L, bilirubin 28 
μmol/L, ALP 132 u/L). Chest X-ray: 
right lower zone consolidation. 
Liver ultrasound: inflammatory 
diffusely hypoechoic liver with a 
raised periportal and 
pericholecystic echogenicity.  
Normal cell count and protein (0.42 g/L) 
MRI brain: increased signal lesion in the right 
inferior cerebellar peduncle extending to involve a 
small portion of the upper cord. The lesion 
measured 13mm in maximum cross-sectional area 
and 28mm in longitudinal extent. There was 
swelling at the affected tissue and associated micro-
haemorrhage. 
 
Treated with oral amoxicillin, no other treatment. 
Gradual improvement in neurological symptoms and 
he was discharged home after 11 days on gabapentin; 
oscillopsia and ataxia persisted. 
  
    Other Encephalopathies                   
      Dugue35 - 1 case 6-week-old infant with cough and 
fever had episodes of bilateral leg 
stiffening and sustained upward 
gaze 
 
RT-PCR positive in 
nasopharyngeal 
swab and anal swab. 
High-throughput 
sequencing showed 
SARS-CoV2 RNA in 
nasopharyngeal 
samples and anal 
swab samples. RT-
PCR negative in 
plasma and CSF. 
 
Nasopharyngeal swab: 
respiratory pathogen PCR 
panel positive for 
rhinovirus/enterovirus, high 
throughput sequencing 
positive for rhinovirus C. CSF: 
meningitis/ encephalitis 
pathogen PCR panel was 
negative and culture 
negative.  
Leucopaenia of 5.07 x10^3 white 
blood cells/μL with a normal 
differential, and elevated 
procalcitonin of 0.21 ng/m. 
Normal U+Es. 
CSF: normal 
MRI brain normal 
Prolonged EEG monitoring: excess of temporal 
sharp transients and intermittent vertex delta 
slowing with normal sleep-wake cycling 
No specific treatment. No further episodes and 
discharged home after one day.  
  
      Helms32 - 49 
cases 
40 had agitation, 26 of the 40 who 
could be evaluated had evidence of 
confusion, 39 had corticospinal 
tract signs (enhanced tendon 
reflexes, ankle clonus, and bilateral 
extensor plantar reflexes). 15 had a 
dysexecutive syndrome at 
discharge (inattention, 
disorientation, or poorly organized 
All positive by RT-
PCR in 
nasopharyngeal 
samples. Negative 
RT-PCR in CSF in 7 
patients. 
NR NR 7 patients had CSF analysis. None had pleiocytosis. 
2 patients had matched oligoclonal bands. 1 patient 
had raised protein. 
13 patients had MRI brain. 8 had enhancement in 
leptomeningeal spaces. 11 patients had perfusion 
imaging, and all had bilateral frontotemporal 
hypoperfusion. 2 patients had acute ischaemic 
stroke. 1 had subacute ischaemic stroke.  
8 patients had EEG. 1 had diffuse bifrontal slowing. 
All required treatment on ITU for severe COVID-19. 45 
had been discharged from ICU at the time of writing.  
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movements in response to 
command). 7 had a history of 
neurological disorders, including 
transient ischemic attack, partial 
epilepsy, and mild cognitive 
impairment. 
 
      Mao31 - 16 cases 16 patients hospitalised with 
COVID-19 had "impaired 
consciousness", of which 1 had a 
seizure characterized by a sudden 
onset of limb twitching and loss of 
consciousness, lasting 3 minutes. 
All positive by RT-
PCR in throat swab. 
NR Patients with 'CNS disease' and 
severe respiratory disease had 
lower lymphocyte levels and 
platelet counts and higher blood 
urea nitrogen levels compared to 
those without CNS symptoms. 
 
NR 
 
13 had severe respiratory disease and 3 non-severe 
according to American Thoracic Society guidelines. No 
further details. 
  
      Poyiadji23 - 1 case Female patient with cough, fever 
and altered mental status. Imaging 
consistent with acute necrotising 
encephalopathy. 
 
RT-PCR positive in 
nasopharyngeal 
swab. CSF RT-PCR 
unable to be 
performed. 
CSF: bacterial culture 
negative after 3 days, and 
'tests' for HSV, VZV and WNV 
negative.  
NR Non-contrast CT head: symmetric hypoattenuation 
within the bilateral medial thalami. Normal CT 
angiogram and CT venogram. MRI brain: T2 FLAIR 
hyperintensity within the bilateral medial temporal 
lobes, thalami and subinsular regions with evidence 
of hemorrhage indicated by hypointense signal 
intensity on susceptibility-weighted images and rim 
enhancement on postcontrast images  
 
IVIG. Outcome not reported   
      Paniz-Mondolfi33 
- 1 case 
74-year-old male with fever, 
confusion and agitation who had 
two falls at home 
 
RT-PCR positive in 
nasopharyngeal 
swab.  Electron 
microscopy of 
frontal lobe 
specimens at post-
mortem: presence 
of viral particles in 
endothelial cells and 
neural cell bodies. 
No indication of if 
this was associated 
with inflammation. 
 
NR Increased CRP, ferritin, d-dimer 
and thrombocytopaenia. Initial 
chest radiology - no changes in 
lung fields, subsequently 
developed new changes bilaterally 
on chest X-ray suggestive of 
consolidation.  
CT head: no acute changes Given hydroxychloroquine and LMWH initially, then 
tocilizumab. Persistently febrile, agitated with 
episodes of hypotension and increasing hypoxia. 
Developed new onset atrial fibrillation and was given 
fluids and amiodarone, reverting to sinus rhythm, then 
continued on metoprolol. Deteriorated and died.  
  
      Zhou - 1 case 56-year-old patient with COVID-19 
pneumonia  
 
SARS-CoV2 detected 
by sequencing in CSF 
NR NR NR 
 
NR   
      
    Acute disseminated encephalomyelitis    
      Zanin39 - 1 case 54-year-old woman presented with 
agitation, decreased conscious level 
and seizures following several days 
of anosmia and ageusia 
RT-PCR positive in 
respiratory sample 
Blood: cultures negative; 
urine: cultures negative.  
Lymphopenia (0.3/mm3) with mild 
elevation of inflammatory markers 
(CRP 41.3 mg/L, Fibrinogen 520 
mg/dL). Chest X-ray: interstitial 
pneumonia 
CSF: Normal 
MRI brain and spine: periventricular confluent 
white matter lesions and numerous high signal cord 
lesions from bulbomedullary junction to T6 level. 
No contrast enhancement. 
 
Treated with antiretrovirals and hydroxychloroquine. 
Clinically deteriorated following admission, becoming 
hypoxic and requiring intubation and mechanical 
ventilation. Treated with high dose dexamethasone. 
Tracheostomy was performed at day 7 and she was 
weaned off the ventilator at day 15. Discharged and 
transferred to rehabilitation without sensorimotor 
deficit after approximately 1 month of admission. 
  
      Zhang38 - 1 case Female patient in her early forties 
with a 9-day history of headache 
and myalgia presented with 
dysphagia, dysarthria, expressive 
dysphasia and encephalopathy. Left 
sided facial weakness. Had fever 
and dyspnoea on admission.  
RT-PCR positive- site 
not specified 
(presumed 
respiratory sample) 
Negative influenza swab and 
a negative rapid 
streptococcus test. CSF: 
negative PCR test for HSV 1 
and 2, HHV 6, VZV, and 
negative Cryptococcus test, 
bacterial cultures negative.  
Mild leukocytosis with 
lymphopenia. Chest X-ray: patchy 
consolidation in the right lower 
lung 
CSF: normal cell count, protein, and glucose.  
MRI brain: extensive areas of high signal in bilateral 
frontoparietal white matter, anterior temporal 
lobes, basal ganglia, external capsules and thalami. 
Some foci demonstrated diffusion weighted 
imaging (DWI) changes and corresponding apparent 
diffusion coefficient (ADC) changes. Magnetic 
resonance 
angiography (MRA) brain and neck: normal 
EEG: no evidence of seizures 
Treated with hydroxychloroquine, ceftriaxone and 
IVIG. Some improvement in dysphagia and dysarthria 
after 5 days. 
  
    Myelitis   
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      Zhao40 -1 case 66-year-old man was admitted with 
fever, dyspnoea and 'asthma'. Five 
days after respiratory symptom 
onset he developed acute flaccid 
paralysis of the lower limbs, urinary 
and faecal incontinence and a 
sensory level at T10.  
 
RT-PCR positive in 
nasopharyngeal 
swab. 
Blood: Negative for EBV, 
influenza A, influenza B, 
adenovirus, coxsackievirus, 
parainfluenza virus, CMV, 
RSV on serum IgM testing. 
Negative for Chlamydia 
pneumoniae, Mycoplasma 
pneumoniae, and TB.  
Lymphopaenia (0.55 ×10^9/L) and 
raised CRP (277 mg/L) and 
procalcitonin (4.33 ng/mL). Slightly 
raised ALT (56 U/L) and AST (50 
U/L). CT Chest: bilateral patchy 
changes. 
CT brain showed lacunar infarcts. Spinal imaging 
not performed 
 
On admission, he deteriorated rapidly and was 
admitted to ICU. Treated with moxifloxacin, 
oseltamivir, lopinavir-ritonavir, ganciclovir, and 
meropenem, followed by dexamethasone and IVIG for 
his neurological symptoms. Required supplementary 
oxygen. Slight improvement in power in upper and 
lower limbs following treatment, but still unable to 
walk. Discharged and transferred for rehabilitation. 
  
  Cerebrovascular disease                         
    Ischaemic stroke   
      Avula48 - 4 cases Four patients, aged 73-88 years old. 
All had a history of hypertension, 3 
dyslipidaemia, 1 diabetes and 
neuropathy, 1 carotid stenosis, 1 
chronic kidney disease. Three 
presented with acute new focal 
neurological deficit (facial droop 
and slurred speech; left-sided 
weakness; right-arm weakness and 
word finding difficulty). One 
presented with altered mental 
status. 
Of these patients, one had fever, 
respiratory distress, nausea, and 
vomiting; one had fever only; 
another had mild shortness of 
breath with a dry cough; and a 
forth had no respiratory symptoms 
nor fever.  
All four had positive 
RT-PCR - presumed 
to be upper 
respiratory samples. 
No mention of CSF 
studies. 
Negative blood and urine 
cultures in the two patients 
for which results were 
reported.  
Three patients had lymphopaenia, 
one with leucopaenia and two 
with leucocytosis. Two had 
elevated D-dimer and 
inflammatory markers. Three had 
patchy changes bilaterally on 
Chest X-ray or CT.   
All four had evidence of unifocal infarcts: three on 
CT, one on MRI brain. 
 
All were treated with antiplatelet therapy - none had 
thrombolysis or thrombectomy. Three required 
intubation and ventilation and all three died. The forth 
was discharged to a rehabilitation facility. 
  
      Benussi42 - 35 
cases 
35 patients: aged an average of 77 
years  
 
All had positive RT-
PCR on a respiratory 
sample. 
NR Patients with cerebrovascular 
disease and COVID-19 had an 
increased neutrophil and platelet 
count, reduced lymphocyte count, 
higher C-reactive protein, 
erythrocyte sedimentation rate, 
lactate dehydrogenase, aspartate 
and alanine aminotransferase, 
prothrombin time and fibrinogen 
levels compared to patients with 
cerebrovascular disease but 
without COVID-19. No details 
specific to ischaemic stroke.  
NR 
 
8/35 had endovascular treatment; 2/35 had 
intravenous fibrinolysis; 3/35 had bridging therapy. 
Median modified Rankin score on discharge was 5 
(severe disability; bedridden). 
  
      Beyrouti47 - 6 
cases 
Patients aged 53-83 years, 5 male, 1 
female. Three had hypertension, 2 
ischaemic heart disease, 2 atrial 
fibrillation, 1 had a previous stroke 
and high BMI, another had 
diabetes, ischaemic heart disease 
and was a smoker with heavy 
alcohol consumption.  Three had 
dysarthria, one expressive 
dysphasia, one aphasia. Four had 
hemiparesis; two had 
incoordination. One had reduced 
consciousness (GCS 13/15).   
All had respiratory symptoms, four 
had fever, at a median (range) of 13 
(-2 to +24) days either before (in 5) 
or after (in 1) neurological 
symptom onset 
All six had positive 
RT-PCR - presumed 
to be upper 
respiratory samples. 
No mention of CSF 
studies. 
One had a medium titre IgM 
anti-cardiolipin antibody and 
low titre IgG and IgM 
aβ2GP1.  
One had a leucocytosis, three had 
lymphopaenia. All had a raised D-
dimer and LDH. Five had a raised 
ferritin, five had a raised CRP. All 
had bilateral patchy changes on 
chest X-ray or CT, two had 
pulmonary emboli - one in a 
segmental artery, the other with 
bilateral emboli in segmental and 
subsegmental arteries.  
Initial scans (CT/MRI brain) showed unifocal infarcts 
in four, one of whom had bilateral infarcts on a 
follow up MRI brain. Two had bilateral infarcts on 
initial scans. 
 
One treated with dual antiplatelet and therapeutic 
low-molecular weight heparin (LMWH) therapy; one 
had external ventricular drain placement and 
therapeutic LMWH; another had apixaban; the fourth 
had therapeutic LMWH; two had intravenous 
thrombolysis. Three required oxygen therapy, two 
were admitted to ITU, one died secondary to COVID-
19 pneumonia following cardiorespiratory 
deterioration. 
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      Gonzales-Pinto49 - 
1 case 
36-year-old woman without 
respiratory symptoms presented 
with 48 hours of aphasia and right 
hemiplegia. 
 
Positive RT-PCR - 
presumed to be 
upper respiratory 
sample. No mention 
of CSF studies. 
NR Leucocytosis (23600 cells/μl) and 
raised CK (8669 U/l), D-dimer 
(7540 ng/ml) and CRP (156 
mg/ml). 
CT Chest revealed a bilateral 
pneumonia and bilateral acute 
pulmonary embolism 
CT brain showed left middle cerebral artery (MCA) 
infarct and mild midline deviation. CT angiography 
showed occlusion of left internal carotid artery, left 
MCA and the anterior cerebral artery, and 
thrombus in the ascending aorta. 
No operative intervention due to poor clinical status 
and severe mass effect; pharmacological therapies not 
reported. Deteriorated, and died 3 days after 
admission.  
  
      Helms32 - 3 cases 
(also reported in 
CNS section)  
"unexplained encephalopathic 
features" while on intensive care 
unit with COVID-19. 
 
All RT-PCR positive 
on nasopharyngeal 
swab 
NR   Unclear if the reported CSF and 
electroencephalography results relate to these 
three patients 
MRI brain: Two small unifocal acute ischemic 
stroke; one unifocal subacute ischemic stroke 
 
All patients admitted to ITU with Acute Respiratory 
Distress Syndrome (ARDS).  
  
      Li41 - 11 cases 11 patients: aged 57-91 years old, 9 
with hypertension, 6 with diabetes, 
3 with cardiovascular disease, 3 
smokers, 1 with malignancy; 6 
female and 5 males; 5 had large-
vessel stenosis; 3 cardioembolic; 3 
small-vessel disease. 
All patients had respiratory 
symptoms a median (range) of 11 
days (range 0-30) before 
neurological manifestations  
All RT-PCR positive 
on throat swab 
NR No specific detail given on the 11 
patients with ischaemic stroke. All 
patients had evidence of COVID-19 
pneumonia on CT chest.  
NR 
 
Nine had severe disease. Six were treated with 
antiplatelet (aspirin or clopidogrel); five were given 
with anticoagulant therapy (Clexane).  Four died; 
seven survived. 
  
      Lodigiani50 - 9 
cases 
Patients aged 57-76, 6 male and 3 
females, two had lung cancer. Six 
presented with stroke; presumed 
the other three presented with 
respiratory illness 
 
"Laboratory-proven 
COVID-19" 
NR 6 patients had a raised D-dimer. 
One also had a pulmonary 
embolism confirmed on CT. No 
additional details given.  
NR 
 
Four received aspirin, three were also given treatment 
dose LMWH, of who one received systemic 
thrombolysis and one a mechanical thrombectomy. 
Four received treatment dose LMWH, three had 
additional treatment - one with clopidogrel, one with 
systemic thrombolysis, another with local lysis and 
mechanical thrombectomy. One had treatment dose 
unfractionated heparin. During admission, one patient 
developed necrotising meningoencephalitis, another 
had disseminated intravascular coagulation. Three 
were admitted to ITU, two died and, at the time of 
reporting, four had been discharged.  
  
      Morassi45 - 4 
cases 
4 patients: aged 64-82 years, 3 with 
hypertension and, 2 with a previous 
stroke/TIA and aortic valve disease, 
1 who was a smoker with a 
previous myocardial infarction. All 
presented primarily with severe 
acute respiratory illness; 3/4 
developed neurological 
manifestations during 
hospitalization (two hemiparesis, 
one inability to rouse when 
sedation held); 1/4 presented with 
episodes of transient loss of 
consciousness followed by 
confusion, in addition to respiratory 
symptoms. 
All RT-PCR positive 
on nasopharyngeal 
swab 
NR All had raised CRP, two had a 
raised d-dimer, two had raised 
LDH, two had abnormal renal and 
liver function tests. CT Chest on all 
patients: bilateral ground glass 
opacities, one patient also had 
bilateral pleural effusions and a 
pulmonary embolism.  
One had CSF: normal leukocyte count, protein and 
IgG index. 
All had multifocal infarcts on CT/MR brain. 
The patient presenting with transient loss of 
consciousness and ensuing confusion had 
electroencephalography: "normal background in 
the alpha range (8 Hz), associated with recurrent 
sharp slow waves over the left temporal region, 
which occasionally were seen also on the right 
homologous regions" 
One was treated with aspirin, clopidogrel and 
enoxaparin; another given levetiracetam; treatment 
not reported for the remaining two. Two were 
intubated and mechanically ventilated. Two died; of 
the two survivors, one had coma (GCS 3/15) and one 
was severely disabled with modified Rankin score of 4. 
  
      Moshayedi53 - 1 
case 
Male, in 70s, no comorbidities 
reported; after 5 days of shortness 
of breath was admitted to hospital 
with ST-elevation myocardial 
infarction and bilateral ischaemic 
lower limbs.  Developed in-hospital 
aphasia with right hemiparesis and 
facial droop. 
RT-PCR positive on 
respiratory 
specimen 
NR Renal failure and activated PTT 
>85.5 while on heparin. 
MRI brain: acute infarct in the left insular, 
temporal, parietal, and frontal lobes; smaller acute 
infarcts in the right caudate and left cerebellar 
hemisphere; haemorrhagic conversion in the left 
fronto-temporal territory. MR angiogram: occlusion 
of left middle cerebral artery proximal M1 segment. 
 
Comfort measures instituted, no other details.    
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      Oxley51 - 5 cases 33-49 years old; 4/5 male. All had 
hemiplegia; 4/5 had reduced 
conscious level. Additionally, three 
had dysarthria, one global 
dysphasia, two had a sensory 
deficit. 
Three had systemic/respiratory 
symptoms. 
All five had positive 
RT-PCR - presumed 
to be upper 
respiratory samples. 
No mention of CSF 
studies. 
NR One had thrombocytopaenia, one 
prolonged PT, one prolonged 
APTT, three with raised fibrinogen, 
three with increased D-dimer, 
three with raised ferritin. CT 
angiography reported in one 
patient: Patchy ground-glass 
opacities in bilateral lung apices  
All had single-territory infarcts on CT or MRI brain 
 
Four had clot retrieval, of whom one had intravenous 
thrombolysis and hemicraniectomy and one had stent 
insertion. Two had apixaban; two aspirin-alone; one 
had dual antiplatelets. One discharged home; two 
discharged to rehabilitation facilities; two remain in 
hospital (one ITU, one stroke unit). 
  
      Zhang46 - 3 cases 3 patients: aged 65-70 years; one 
female; three with hypertension, 
two with previous stroke, one 
known diabetes and coronary 
artery disease, and one with 
emphysema and nasopharyngeal 
carcinoma presented with 
symptoms of infection. One 
required invasive ventilation, at 
which point he had ischaemia of 
lower limbs and a few fingers on 
the left hand. The other two 
patients had "similar findings". 
Onset of neurological 
manifestations occurred at 10, 18 
and 33 days after COVID-19 
symptom onset- all had fever and 
dyspnoea, two with cough, two 
with headache and one with 
diarrhoea.  
"Severe acute 
respiratory 
syndrome 
coronavirus 2 (SARS-
CoV-2) infection was 
confirmed in all the 
patients by reverse-
transcriptase–
polymerase-chain-
reaction (RT-PCR) 
assay or serologic 
testing." 
 Antiphospholipid antibodies 
were detected in all three - 
anti-cardiolipin IgA antibody 
and low titre aβ2GP1 IgA and 
IgM. 
All three had a raised CRP and D-
dimer. Two had lymphopaenia, 
two thrombocytopaenia, one had 
raised LDH. CT Chest: bilateral 
pulmonary infiltrates in all three, 
ground glass opacity in two.  
Imaging showed multifocal cerebral infarctions. 
 
All patients were admitted to ITU. One was intubated 
and mechanically ventilated due to hypoxaemic 
respiratory failure. There is minimal detail about the 
other two and no information on mortality.  
  
    Intracerebral haemorrhage                   
      Al Saeigh43 – 1 
case 
31-year-old man presented after 
one week of malaise, mild fever, 
cough and arthralgia with sudden 
onset of headache and loss of and 
loss of consciousness. Some 
confusion after first operation.  
RT-PCR positive in 
nasal swab. CSF RT-
PCR negative on two 
samples. 
NR NR CT head: subarachnoid haemorrhage in the 
posterior fossa; subsequent CT showed 
hydrocephalus; cerebral angiogram showed 
ruptured dissecting right posterior– inferior 
cerebellar artery aneurysm 
 
External ventricular drain inserted initially; then flow-
diverting stent placed to treat ruptured aneurysm. 
Intubated for surgery but did not require ongoing 
ventilator support. Post-operative confusion resolved; 
discharged for rehabilitation. 
  
      Benussi42 – 3 
cases 
3 patients: no disaggregated clinical 
details provided. 
 
All had positive RT-
PCR on a respiratory 
sample. 
NR Patients with cerebrovascular 
disease and COVID-19 had an 
increased neutrophil and platelet 
count, reduced lymphocyte count, 
higher CRP, ESR, LDH, AST, ALT, 
PTT and fibrinogen compared to 
non-COVID-19 patients. 
NR 
 
NR   
      Li41 – 1 case 62-year-old man with history of 
smoking developed stroke 
symptoms 9 days after onset of 
COVID-19 respiratory/systemic 
symptoms. 
 
RT-PCR positive on 
throat swab 
NR NR NR 
 
Died 22 days after the stroke.   
      Morassi45 – 2 
cases 
Two patients: both 57-year-old men 
were admitted to hospital with 
critical COVID-19. At 7 and 11 days 
later (14 and 17 days after onset of 
respiratory symptoms - both had 
cough and fever, one with 
dyspnoea) they were found to have 
bilaterally fixed dilated pupils and 
coma (GCS 3/15). 
 
Both RT-PCR positive 
on nasopharyngeal 
swab 
NR Both had raised CRP, LDH, AST and 
gamma GT. CT chest showed 
diffuse bilateral ground glass 
opacities in both patients.  
One had bilateral cerebellar haemorrhages on CT 
brain, with hydrocephalus. The other had a large 
frontal haemorrhage with displaced ventricles and 
multiple smaller haemorrhages. 
 
Both developed respiratory failure, requiring 
intubation and ventilation and admission to ICU. Both 
deteriorated neurologically, and imaging confirmed 
cerebral haemmorhage; both died.  
  
      Sharifi-Razavi44 – 
1 case 
79-year-old man had acute loss of 
consciousness and bilateral 
extensor plantar reflexes 3 days 
after onset of fever and cough  
RT-PCR positive on 
oropharyngeal swab 
  Lymphopaenia, raised CRP and 
ESR. CT chest: ground-glass 
opacity in the left lower lobe 
CT head: massive intracerebral haemorrhage in the 
right hemisphere, with intraventricular and 
subarachnoid haemorrhage 
 
NR   
 23 
    Cerebral venous sinus thrombosis                      
      Li41 - 1 case 32-year-old man with history of 
smoking developed neurological 
features 14 days after initial 
presentation with COVID-19  
RT-PCR positive on 
throat swab 
NR NR NR 
 
Treated with anticoagulation; survived but remains in 
hospital. 
  
  Peripheral Nervous System Disease                       
    Guillain Barré syndrome                       
      Alberti61 - 1 case 71-year-old male with paresthesia 
in hands and feet, rapidly 
progressive symmetrical weakness 
more marked in lower limbs than 
upper; areflexia, plantar response 
preserved; lower back pain; 
autonomic disturbance 
(hypertension) 
 'The week before' neurological 
symptom onset: fever; during 
admission developed dyspnoea and 
was hypoxic 
RT-PCR positive in 
nasopharyngeal 
swab on admission, 
3 days after neuro 
symptom onset 
NR Chest CT: multiple bilateral ground 
glass opacities and consolidation 
CSF: mild leucocytosis (9 cells/ul), raised protein (54 
mg/dL), 
CT Head: normal 
Nerve conduction study and electromyography: 
Severe acute inflammatory demyelinating 
polyneuropathy  
Treated with IVIG for 5 days. Required oxygen support 
(60-80%) and was started on non-invasive ventilation 
(CPAP). Deteriorated and died.  
  
      Camdessanche60 - 
1 case 
64-year-old male with a 2-day 
history of cough and fever 
presented following a fall. On day 9 
of hospital admission, he developed 
paresthesia in his hands and feet, 
and progressive weakness in all 
four limbs with areflexia and loss of 
vibration sense. He developed 
dysphagia and respiratory 
insufficiency.  
RT-PCR positive in 
nasopharyngeal 
swab on admission, 
9 days before neuro 
symptom onset 
Negative for Campylobacter 
jejuni, Mycoplasma 
pneumoniae, Salmonella 
enterica, CMV, EBV, HSV1 & 
2, VZV, Influenza virus A & B, 
HIV and hepatitis E. Serum: 
Anti-ganglioside antibodies 
not detected. 
CT chest: 10–25% ground glass 
opacities. 
CSF: normal cell count, raised protein (166 mg/dl), 
Nerve conduction study and electromyography: 
acute inflammatory demyelinating polyneuropathy  
He had initially needed 2-3L of oxygen via nasal 
cannula but had been weaned off it prior to 
neurological symptom onset. Given lopinavir/ritonavir. 
Treated with IVIG for 5 days, developed respiratory 
insufficiency and required admission to ICU for 
intubation and mechanical ventilation. No other 
details on outcome given.  
  
      Toscano65 - 5 
cases 
5 patients, 4 males and 1 female, 
aged 23-77 years old. 4 patients 
had flaccid, areflexic limb weakness 
- 3 with quadriparesis or 
quadriplegia and 1 with paraplegia - 
3 of 4 of these patients had facial 
weakness, 2 had dysphagia, and 3 
developed respiratory failure. 1 
patient had facial diplegia and 
areflexia with limb paraesthesia 
and ataxia.  
Patients presented a median 
(range) of 7 (5-10) days after 
respiratory symptoms: cough in 4, 
fever in 3, hyposmia/anosmia or 
ageusia in 3 and pharyngitis in 1. 
4 patients RT-PCR 
positive in 
nasopharyngeal 
swab. One positive 
by serological test. 
RT-PCR in CSF 
negative in all 
patients. 
1 patient (patient 5)-
negative for Campylobacter 
jejuni, EBV, CMV, HSV, VZV, 
influenza, and HIV. 3 
patients tested for 
antiganglioside antibodies, 
but none were detected.  
1 - CT scan of the thorax revealed 
interstitial bilateral pneumonia; 2- 
no details; 3 - CT scan of the 
thorax revealed multiple bilateral, 
ground-glass opacities compatible 
with interstitial pneumonia; 4- ; 
chest imaging was 
'negative'; 5- X-ray and CT showed 
interstitial pneumonia, without 
parenchymal opacities nor 
alveolar damage; 
CSF analysis: all patients had normal WCC, 3 
patients had elevated protein. 
MRI: enhancement of caudal nerve roots in 2 
patients, enhancement of facial nerve in one, and 
no signal change in 2.  
Nerve conduction study:  axonal pattern in 3 
patients, demyelinating in 2.  
All treated with IVIG, 2 had 2 cycles, one also had 
plasma exchange. 3 required mechanical ventilation. 
At 4 weeks: 2 were still ventilated in intensive care, 2 
were having physiotherapy and one was discharged. 
  
      Zhao56 - 1 case 61-year-old female with progressive 
weakness of her lower limbs, then 
upper limbs, and severe fatigue; 
areflexia in lower limbs, and 
decreased sensation distally.  
7 days after neurological symptom 
onset she developed a dry cough 
and fever.  
RT-PCR positive in 
oropharyngeal 
swab.  
NR laboratory results on admission 
were clinically significant for 
lymphocytopenia (0·52×10^9/L, 
normal: 1·1–3·2×10^9/L) and 
thrombocytopenia (113×10^9 /L, 
normal: 125–300×10^9/L). CT 
chest: ground glass opacities 
bilaterally.  
CSF: normal cell count, raised protein (124 mg/dL), 
Nerve conduction study: acute inflammatory 
demyelinating polyneuropathy  
Treated with IVIG for 5 days. Also given arbidol, 
lopinavir, and ritonavir. Improved neurologically - 
normal power and reflexes on discharge at day 30.  
  
    GBS variants and other neuropathies                     
      Gutierrez Ortiz68 - 
1 Miller Fisher 
Syndrome 
50-year-old man with a 5-day 
history of cough, fever, malaise, 
headache, back pain, anosmia and 
ageusia developed right 
internuclear opthalmoparesis with 
right fascicular oculomotor palsy, 
RT-PCR positive in 
oropharyngeal 
swab, negative in 
CSF 
Antiganglioside antibody 
GD1b-IgG detected in serum. 
Negative for anti-GM1, GM2, 
GM3, GD1a, GD1b, GD3, 
GT1a, GT1b, GQ1b, and anti-
sulfatide antibodies. Normal 
CSF cytology, sterile cultures 
Lymphopaenia, elevated CRP.  
Chest X-ray: normal.  
 
CSF: normal opening pressure, cell count, raised 
protein (80 mg/dL), normal glucose. 
CT brain with contrast: normal 
 
Treated with IVIG for 5 days, complete recovery at 2 
weeks, except for residual anosmia and ageusia. 
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ataxia and areflexia (preserved 
plantar responses). 
and negative anti-pathogen 
antibody tests. 
 
      Dinkin67 - 1 
ophthalmoplegia 
71-year-old female presented with 
isolated ophthalmoplegia after ‘a 
few days’ of cough and fever. 
Unable to abduct her right eye - 
right abducens palsy 
 
RT-PCR positive in 
nasal swab 
 NR 
 
Leucopaenia 
Chest X-ray: bilateral opacities 
CSF: Normal opening pressure  
MRI brain: enhancement of the optic nerve sheaths 
and posterior Tenon capsules 
Treated with hydroxychloroquine and oxygen. 
Discharged after 6 days. Symptoms improving, 
although ongoing, at 2 weeks post-discharge  
  
      Gutierrez Ortiz68 - 
1 bilateral 
ophthalmoplegia 
39-year-old man with 3 days of 
fever and diarrhoea developed 
diplopia. He had abduction deficits 
in both eyes and fixation 
nystagmus, consistent with bilateral 
abducens palsy, global areflexia and 
ageusia.  
RT-PCR positive in 
oropharyngeal 
swab, negative in 
CSF 
Normal CSF cytology, sterile 
cultures and negative anti-
pathogen antibody tests. 
Leucopaenia, blood tests 
otherwise normal. 
Chest X-ray: normal. 
CSF: normal cell count, raised protein (62 mg/dL) 
CT brain: normal 
 
No specific treatment. Complete recovery in 2 weeks.   
      Pellitero69 - 1 
acute vestibular 
dysfunction  
30-year-old female developed 
unsteadiness, disequilibrium and 
nausea, worse on standing. 3 weeks 
before, she reported 10 days of 
anosmia and ageusia. She was 
unable to walk without assistance. 
Horizontal nystagmus with a rapid 
phase to the right, oscillopsia. 
Romberg positive. 
RT-PCR positive on 
admission, sample 
tested was not 
reported. 
 NR Lymphocytopaenia (1000 
cells/mm3 ), D-dimer level of 2270 
ng/mL, fibrinogen level of 326 
mg/dL, LDH level of 235 U/L, and 
C-reactive protein level of 1.2 
mg/L. 
Chest CT angiogram: normal 
 
MRI brain with contrast: normal. 
 
Treated with antiemetics and vestibular suppressants, 
the patient improved.  
  
    Rhabdomyolysis and other muscle disease                     
      Jin70 - 1 case of 
rhabdomyolysis 
60-year-old man admitted with 
COVID-19 developed weakness and 
tenderness in lower limbs 15 days 
after onset of fever and cough.  
RT-PCR positive in 
throat swab 
 Urine: blood and protein 
detected 
 
Leucopaenia, raised CRP and LDH. 
Normal U+Es and LFTS and CK 
initially, then raised CK: 11,842 
U/L, myoglobin: 12,000 mg/L, AST 
and ALT. 
CT Chest: ground glass opacities 
 
NR Worsening respiratory status following admission.  
Antibiotics and supportive therapy, the patient’s 
neuromuscular symptoms improved over several days. 
  
    Taste and smell dysfunction                     
      Lechien74 - 357 
cases 
357 (86%) with smell dysfunction; 
342 (89%) with taste dysfunction 
All RT-PCR positive 
in respiratory 
samples 
   NR NR Treated with nasal corticosteroids (8%), oral 
corticosteroids (2.5%), nasal irrigation (17%) 
  
                            
        ADEM = acute disseminated encephalomyelitis; ALT = alanine aminotransferase ; AST = aspartate aminotransferase; CK = creatinine kinase; CRP = C-reactive protein; CSF = cerebrospinal fluid; CT = computed tomography; CVST = cerebral 
venous sinus thrombosis; EBV = Epstein-Barr virus; EEG = electroencephalogram; EMG = electromyography;  ESR = erythrocyte sedimentation rate; FLAIR = fluid-attenuated inversion recovery (MRI sequence); GBS = Guillain-Barré 
syndrome; Hb = haemoglobin; HSV = Herpes Simplex virus; ICU = intensive care unit; IVIG = intravenous immunoglobulin; LFTs = liver function tests; LDH = lactate dehydrogenase; NCS = nerve conduction study; MRI = magnetic resonance 
imaging; PTT = prothrombin time; RT-PCR = reverse transcription polymerase chain reaction; T2WI= T2-weighted image (MRI sequence); U+Es= urea and electrolytes; VZV= Varicella Zoster virus; WCC = white cell count  
  
  
  
        Table 2. Neurological manifestations associated with COVID-19                
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Table 3. Provisional case definitions for neurological diseases associated with COVID-19, based on previously established principles95,97,98 
  Confirmed Probable  Suspected 
WHO COVID-19 case definitions99  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A person with laboratory confirmation100 of 
SARS-CoV-2 infection, irrespective of clinical 
signs and symptoms.  
 
Confirmatory tests include a nucleic acid 
amplication test (e.g. RT-PCR) or validated 
antibody test, 
 
•In an area WITH established circulation of 
virus:  one positive RT-PCR test or identification 
of virus on sequencing. One or more negative 
tests do not rule out infection if clinical 
suspicion. 
 
•In an area WITHOUT established circulation of 
virus: one positive RT-PCR test for two different 
viral genome targets, OR one positive result with 
partial or whole genome sequencing 
A suspect case, for whom testing for the COVID-19 virus is 
inconclusive 
 
OR 
 
A suspect case, for whom testing could not be performed for 
any reason 
A patient with acute respiratory illness (fever and at least one 
sign/symptom of respiratory distress) AND history of travel to 
or residence in a location reporting community transmission of 
COVID-19 disease during the 14 days prior to onset  
 
OR  
 
A patient with acute respiratory illness (fever and at least one 
sign/symptom of respiratory distress) AND having been in 
contact with a confirmed or probable case in the last 14 days 
prior to symptom onset 
 
OR 
 
A patient with severe acute respiratory illness (fever and at 
least one sign/symptom of respiratory distress  AND requiring 
hospitalisation) AND in the absence of an alternative 
explanation that fully explains the clinical presentation 
 
  Confirmed Probable  Possible 
SARS-CoV-2 meningitis, encephalitis, 
myelitis/myelopathy** 
 
 
 
 
 
 
 
 
 
SARS-CoV-2 detected in CSF/ brain tissue †,  
OR 
Evidence of SARS-CoV-2-specific intrathecal 
antibody; 
 
AND 
 
No other explanatory pathogen or cause found 
 
 
SARS-CoV-2 detected in respiratory or other non-CNS 
sample ‡, 
OR 
Evidence of SARS-CoV-2-specific antibody in serum 
indicating acute infection+§; 
 
AND 
 
No other explanatory pathogen or cause found 
Patient meets suspected case definition of COVID-19 
according to national or WHO guidance (as below), based on 
clinical symptoms and epidemiological risk factors. 
 
In the context of known community SARS-CoV-2 transmission, 
supportive features* include: 
Clinical: new onset of least one of: cough, fever, muscle aches, 
loss of smell, loss of taste;  
Laboratory: lymphopenia, raised d-dimer;  
Radiological: evidence of abnormalities consistent with 
infection or inflammation (e.g. ground glass changes) 
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  Strong association Probable association Possible association 
Acute disseminated 
encephalomyelitis** (ADEM) 
associated with SARS-CoV-2 infection  
 
 
 
 
 
 
 
 
 
  Neurological disease onset <= 6 weeks after acute infection,  
 
AND 
 
SARS-CoV-2 RNA detected in any sample,  
OR 
 
Neurological disease onset <= 6 weeks after acute infection,  
 
AND 
 
SARS-CoV-2 RNA detected in any sample;  
OR 
Antibody evidence of acute SARS-CoV-2 infection; 
 
AND 
 
 
Antibody evidence of acute SARS-CoV-2 infection; 
 
 AND 
No evidence of other commonly associated causes Evidence of other commonly associated causes 
Guillain-Barré syndrome** and other 
acute neuropathies associated with 
SARS-CoV-2 infection  
 
 
 
 
 
 
 
 
  Neurological disease onset <= 6 weeks after acute infection,  
 
AND 
 
SARS-CoV-2 RNA detected in any sample;  
OR 
Neurological disease onset <= 6 weeks after acute infection,  
 
AND 
 
SARS-CoV-2 RNA detected in any sample;  
OR 
Antibody evidence of acute SARS-CoV-2 infection; 
 
AND 
Antibody evidence of acute SARS-CoV-2 infection;  
 
AND 
 
 
No evidence of other commonly associated causes ¶ Evidence of other commonly associated causes ¶ 
CNS vasculitis** associated with SARS-CoV-2 
infection 
 
 
 
 
 
 
 
 
SARS-CoV-2 detected in CSF/brain tissue†;  
OR  
Evidence of SARS-CoV-2-specific intrathecal 
antibody;  
 
AND 
 
The presence of histopathological features of 
angiitis within the brain 
 
 SARS-CoV-2 detected in CSF/brain tissue†;  
OR  
Evidence of SARS-CoV-2-specific intrathecal antibody;  
 
AND 
 
Laboratory and imaging support for brain inflammation (MR 
scan evidence compatible with CNS vasculitis with 
characteristic angiographic changes; elevated levels of 
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AND 
 
No other explanatory pathogen or cause found 
cerebrospinal fluid protein and/or cells, and/or the presence 
of oligoclonal bands) 
 
AND 
 
No other explanatory pathogen or cause found 
Stroke** associated with SARS-CoV-2 
infection 
 
 
 
 
 
 
 
 
 
 
 
SARS-CoV-2 detected in CSF or other sample‡;  
OR 
Evidence of SARS-CoV-2-specific antibody in serum 
indicating acute infection; 
 
AND 
 
No other known traditional cardiovascular risk 
factors¥ 
SARS-CoV-2 detected in CSF or other sample;  
OR 
Evidence of SARS-CoV-2-specific antibody indicating acute 
infection; 
 
AND 
 
Other traditional cardiovascular risk factors¥ 
 
 
*These case definitions are suggestions based on published information to date; they are likely to need refining as more data emerge.  
**See Supplementary Material for case definitions of meningitis, encephalitis, myelitis/myelopathy, acute disseminated encephalitis, Guillain-Barré Syndrome, and stroke, TIA and central nervous system vasculitis.  
 
† detection in CSF or brain tissue by PCR, culture, or immunohistochemistry, as appropriate; ‡ detection in non-CNS sample by PCR or culture. § Serological evidence of acute infection can be defined as i) detection of 
IgM, or ii) IgG seroconversion or iii) >=4-fold rise in antibody titres in paired acute and convalescent serum samples. ¶ These include: infection with one of Campylobacter jejuni, Mycoplasma 
pneumoniae,  Cytomegalovirus (CMV), Epstein–Barr virus (EBV), hepatitis E virus, Zika virus, or HIV; or vaccination in the last 6 weeks. Associated causes may differ depending on geographical location. ¥ traditional 
cardiovascular risk factors include; hypertension, current smoker, diabetes, hypercholesterolemia, and atrial fibrillation.   
 
The terms ‘confirmed’, ‘probable’ and ‘suspected’ are used in the WHO COVID-19 case definition. The terms ‘confirmed’, ‘probable’ and ‘possible’ for COVID-19 meningitis, encephalitis or myelitis and ‘strong 
association’, ‘probable association’, ‘possible association’ reflect the terminology used for the different syndromes in the original publications from which this table derives (see table references). 
 
 
 Table 3. Provisional case definitions for neurological diseases associated with COVID-19, based on previously established principles95,97,98  
 
Figures 
1. a) Brain imaging in two patients with central nervous system disease associated with COVID-19  
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A-H) Patient 1 - Acute Necrotising Encephalopathy associated with SARS-CoV2 infection23 
Magnetic resonance images demonstrate T2 Fluid-attenuated inversion recovery (FLAIR) hyperintensity within the bilateral medial temporal lobes and thalami (A, 
B, E, F) with evidence of haemorrhage indicated by hypointense signal intensity on susceptibility-weighted images (C, G) and rim-enhancement on postcontrast 
images (D, H). 
 
I-K) Patient 2 - Encephalitis associated with SARS-CoV2 infection24 
Diffusion weighted images (DWI) showed hyperintensity along the wall of inferior horn of right lateral ventricle (I); FLAIR images showed hyperintense signal 
changes in the right mesial temporal lobe and hippocampus with slight hippocampal atrophy (J, K). These findings indicated right lateral ventriculitis and 
encephalitis mainly on right mesial lobe and hippocampus. 
 
 
 
 
 
 
 
b) Brain imaging in four patients with COVID-19 and acute cerebrovascular disease47 
 
I J K
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A, B) Patient 1 – A 64-year-old male with COVID-19 developed mild left arm weakness and incoordination on day 15 of illness, followed by acute bilateral 
incoordination and right homonymous hemianopia a week later. A) MRI brain (day 15) shows intradural left vertebral artery occlusion and acute left posterior 
inferior cerebellar artery territory infarct with petechial haemorrhage; B) MRI brain (day 22) shows extensive acute posterior cerebral artery territory infarction. 
C, D) Patient 2 - 53-year-old female, on anticoagulation for atrial fibrillation (AF), presented 24 days after respiratory symptom onset with acute confusion, 
incoordination and drowsiness; C and D) CT brain imaging shows acute large left cerebellar and right parieto-occipital infarcts.  
E, F) Patient 3 - 85-year-old male presented 10 days after COVID-19 symptom onset with dysarthria and right hemiparesis. He had AF, hypertension and ischaemic 
heart disease. E and F) CT brain shows left posterior cerebral artery occlusion and infarction.  
G, H) Patient 4 - 61-year-old male with a history of previous stroke presented with  dysarthria and left hemiparesis two days before respiratory symptom onset; 
SARS-Cov-2 was detected on PCR testing. G and H) MRI brain shows an acute right striatal infarct 
 
 
 
 
 
 
 
 
 
2. a) Diagnostic testing, clinical presentation and pathogenesis in COVID-19 and neurological disease.  
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b) Potential mechanisms of COVID-19 neurological disease based on knowledge of other viruses.  
Direct viral infection (A) 
Vascular (C)
RT-PCR SARS-CoV-2
Time
14 days7 days
Post-infectious (D)
Weeks
IgM
IgG
Antibody
Neurological Syndromes
0 days
43 5 6
Cough, fever, tiredness, myalgia, headacheSystemic or respiratory symptoms
Onset of systemic and/or respiratory 
symptoms of infection 
Para-infectious (B)
Pathogenesis
Clinical presentation
Diagnostic testing
Neurological disease mechanisms
GBS (-7 to 24)
Encephalitis (-2 to 17)
ADEM (9)
Cerebrovascular disease (-2 to 33)
- 7 days
Myelitis (5)
Viral RNA
// //
6 12
Months
Blue bars represent the time period over which SARS-CoV-2, anti-SARS-CoV-2 IgM or IgG antibodies are detectable on either reverse transcriptase 
polymerase chain reaction (RT-PCR) or antibody testing. Red bars represent the time of clinical presentation, including the duration of systemic/respiratory 
symptoms of COVID-19, or when patients have presented with suspected COVID-19-associated neurological disease relative to onset of COVID-19 symptoms.  
Green bars represent pathological mechanisms that may result in neurological disease in COVID-19, as in other viruses; (A), (B), (C), and (D) refer to figure 2b. 
Approximate values are based on currently published data. Bars are faded to indicate lack of certainty over specific ranges. The dynamics of anti-SARS-CoV-2 
IgG antibody production are not known beyond a few weeks, although by analogy with other viruses, immunity might be expected for months to years.     
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BBB= blood-brain barrier  
A) Virus may enter the nervous system across the blood brain barrier, possibly by infected leukocytes, or through retrograde transport along the olfactory or other cranial or peripheral 
neurons.78 Viruses can enter neurons to cause cytopathology.  
B) Innate immune responses to viral infection and resultant inflammation may cause tissue damage, as is thought to occur in acute encephalopathy syndromes in influenza infection.15 
C) Pathological adaptive immune responses include damage caused by cytotoxic T cells101 and antibody mediated response against host tissue, either in the central or peripheral 
nervous system.55,102 The latter may be caused by molecular mimicry between the pathogen and host epitopes, or tissue damage may result in failure of tolerance to self-antigens. 
D) Viral infection may cause blood vessel damage either by direct infection or immune-mediated vasculitis.103 Alternatively, the virus may activate the vessel endothelium triggering 
inflammatory and thrombotic pathways with release of microparticles leading to thrombotic microangiopathy, as part of a secondary haemophagocytic lymphohistiocytosis,86 a 
syndrome of excessive inflammation and tissue destruction due to abnormal immune activation, thought to be related to excessive and inadequately regulated lymphocyte and 
macrophage activity. 
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